CSL Limited
(ASX:CSL) has announced that the US FDA has approved IDELVION, CSL’s long-acting albumin fusion protein for the treatment of haemophilia B.
The company says IDELVION delivers high-level protection with up to a 14-day dosing in appropriate patients, providing excellent bleeding control.
The product will be added to CSL’s growing portfolio of bleeding disorder products.
Haemophilia B is a congenital bleeding disorder, affecting one in 25,000 male births.
CSL reported a net profit of $983.85 million at 31 December 2015.
